[Sublingual captopril: indications and advantages?].
Meyer
G J
GJ
Klinik für Nephrologie Christian-Albrechts-Universität, Kiel. aghyp@nephro.uni-kiel.de
D000284:Administration, Oral; D000286:Administration, Sublingual; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology; D002216:Captopril / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D004630:Emergencies; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D009543:Nifedipine / Q000008:administration & dosage / Q000494:pharmacology; D011224:Prazosin / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D002216:Captopril; D009543:Nifedipine; D011224:Prazosin